Ideon Gateway
Scheelevägen 27
Lund 223 63
Sweden
46 4 62 75 62 60
https://cantargia.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 23
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Goran Forsberg | Chief Executive Officer | 4.39M | N/A | 1963 |
Mr. Thoas Fioretos M.D., Ph.D. | Founder & Scientific Advisor | 355k | N/A | 1962 |
Mr. Marcus Järås | Founder & Scientific Advisor | N/A | N/A | N/A |
Mr. Kjell Sjöström | Founder | N/A | N/A | N/A |
Mr. Patrik Renblad | Chief Financial Officer | N/A | N/A | 1970 |
Ms. Liselotte Larsson | Chief Operating Officer | N/A | N/A | 1963 |
Dr. David Liberg | Chief Scientific Officer | N/A | N/A | 1969 |
Nina Valkama | Executive Assistant of Administration & Finance | N/A | N/A | N/A |
Dr. Dominique Tersago | Chief Medical Officer | N/A | N/A | 1962 |
Johanna Christensen | Financial Controller | N/A | N/A | N/A |
Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Cantargia AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.